

New Delhi, 4<sup>th</sup> July, 2018

**ORDER**

**S.O. 3241(E)** In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S.O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/ revises the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

**TABLE**

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)	Review Order number and date	Existing SO number and date
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1.	Digoxin	Oral Liquid 0.05mg/ml	1 ML	1.19	31015/100/2017- Pricing dated 07.05.2018	1461(E) dated 02.04.2018 (at Sl. No. 263)
2.	Furosemide	Oral Liquid 10mg/ml	1 ML	2.60	31015/101/2017- Pricing dated 07.05.2018	1461(E) dated 02.04.2018 (at Sl. No. 340)

**Note:**

- All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
- All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/190/58/2018/F

F. No. 8(58)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 4<sup>th</sup> July, 2018

**ORDER**

S. O. 3242(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (8) thereof;

**Table**

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Retail Price (Rs.)	Review Order number and date	Existing SO number & date	Manufacturer & Marketing Company respectively
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
1.	Atorvastatin + Clopidogrel Capsule (Atocor CV 10)	Each hard gelatin capsule contains: Atorvastatin 10mg Clopidogrel 75mg	1 Capsule	10.92	31015/09/2018- Pricing dated 29.05.2018	3915(E) dated 18.12.2017 (at Sl. No. 50)	M/s Windlas Biotech Pvt. Ltd. / M/s Dr. Reddy's Laboratories Ltd.
2.	Atorvastatin + Clopidogrel Capsule (Atocor CV 20)	Each hard gelatin capsule contains: Atorvastatin 20mg Clopidogrel 75mg	1 Capsule	15.625	31015/09/2018- Pricing dated 29.05.2018	02(E) dated 01.01.2018 (at Sl. No. 10)	M/s Windlas Biotech Pvt. Ltd. / M/s Dr. Reddy's Laboratories Ltd.
3.	Telmisartan + Chlorthalidone Tablet (Tigatel CH 80)	Each film coated tablet contains: Telmisartan IP 80mg Chlorthalidone IP 12.5mg	1 Tablet	13.06	31015/13/2018- Pricing dated 29.05.2018	02(E) dated 01.01.2018 (at Sl. No. 04)	M/s Sun Pharma Laboratories Limited
4.	Cefixime + Ofloxacin Tablet (Ranixime Plus)	Each film coated tablet contains: Cefixime Trihydrate eq. to Cefixime anhydrous IP 200mg, Ofloxacin IP 200mg	1 Tablet	10.59	31015/6/2018- Pricing dated 29.05.2018	3915(E) dated 18.12.2017 (at Sl. No. 40)	M/s Theon Pharmaceuticals Limited / M/s Sun Pharmaceutical Industrial Limited
5.	Rosuvastatin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Capsule	16.60	31015/12/2018- Pricing dated 08.06.2018	02(E) dated 01.01.2018 (at Sl. No. 14)	M/s Synokem Pharmaceuticals Ltd. / M/s Eris Lifesciences Limited
6.	Rosuvastatin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets)	1 Capsule	16.06	31015/14/2018- Pricing dated 29.5.2018	02(E) dated 01.01.2018 (at Sl. No. 5)	M/s. Synokem Pharmaceuticals Ltd. / M/s Zydus Healthcare Ltd.

Note:

- (a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

PN/190/58/2017/F

F. No. 8(58)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 4th July, 2018

**ORDER**

S. O. 3240(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

**Table**

<b>Sl. No.</b>	<b>Name of the Formulation / Brand Name</b>	<b>Strength</b>	<b>Unit</b>	<b>Manufacturer &amp; Marketing Company</b>	<b>Retail Price (Rs.)</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>	<b>(6)</b>
1.	Rosuvastatin + Clopidogrel Capsule (Crevast CV 20)	Each Hard gelatine capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg.	1 Capsule	M/s Synokem Pharmaceuticals Ltd/ M/s Eris Lifesciences Ltd.	16.73
2.	Fluconazole Dispersible Tablet (ULTICAN - 50 DT)	Each uncoated tablet contains: Fluconazole IP 50mg	1 Tablet	M/s Acme Formulations Pvt. Ltd. / M/s Sun Pharmaceutical Industries Ltd.	6.24
3.	Amoxicillin + Clavulante Dry Syrup (Clanoxy Forte)	Each 5ml of reconstituted Suspension: Amoxicillin Trihydrate IP eq. to Amoxicillin 400mg, Potassium Clavulante Diluted IP eq. to Clavulnic Acid 57mg	1 ML	M/s Galpha Laboratories Limited	3.219
4.	Telmisartan + Metoprolol Tablet (Metolar TL 50)	Each film coated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (ER)	1 Tablet	M/s Revenbhel Biotech Ltd./ M/s Cipla Ltd.	11.05
5.	Telmisartan + Metoprolol Tablet (Metolar TL 25)	Each film coated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 23.50mg eq. to Metoprolol Tartrate 25mg (ER)	1 Tablet	M/s Revenbhel Biotech Ltd. / M/s Cipla Ltd.	9.22
6.	Hydroxychloroquine Sulphate Tablet (OXCQ 300mg)	Each film coated tablet contains: Hydroxychloroquine Sulphate 300mg	1 Tablet	M/s Wallace Pharmaceuticals Pvt. Ltd.	9.58
7.	Glimepiride + Metformin Tablet	Each film coated bilayered tablet contains: Glimepiride 3mg, Metformin SR 500mg	1 Tablet	M/s Swiss Garnier Genexiaa Sciences / M/s Glenmark Pharmaceuticals Ltd.	6.89
8.	Glimepiride + Metformin + Voglibose Tablet	Each film coated bilayered tablet contains: Glimepiride 2mg, Metformin SR 500mg	1 Tablet	M/s Swiss Garnier Genexiaa Sciences / M/s Glenmark Pharmaceuticals Ltd.	11.01

		Voglibose 0.3mg Tablets			
9.	Glimepiride + Metformin + Voglibose Tablet	Each film coated bilayered tablet contains: Glimepiride 2mg, Metformin SR 1000mg Voglibose 0.2mg Tablets	1 Tablet	M/s Swiss Garnier Genexiaa Sciences / M/s Glenmark Pharmaceuticals Ltd.	11.61
10.	Glimepiride + Metformin + Voglibose Tablet	Each film coated bilayered tablet contains: Glimepiride 1mg, Metformin SR 500mg Voglibose 0.3mg Tablets	1 Tablet	M/s Swiss Garnier Genexiaa Sciences / M/s Glenmark Pharmaceuticals Ltd.	9.40
11.	Telmisartan + Clinidipine + Chlorthalidone Tablet	Each film coated bilayered tablet contains: Telmisartan IP 40mg, Clinidipine 10mg & Chlorthalidone IP 6.25mg	1 Tablet	M/s Swiss Garnier Genexiaa Sciences / M/s Glenmark Pharmaceuticals Ltd.	10.37
12.	Clonazepam + Propranolol Tablet	Each uncoated tablet contains: Clonazepam IP 0.50mg, Propranolol Hydrochloride IP 20mg	1 Tablet	M/s Akums Drugs & Pharmaceutical Limited / M/s Emcure Pharmaceuticals Limited	4.12
13.	Telmisartan + Chlorthalidone Tablet (Telpha-CH)	Each uncoated bilayered tablet contains: Telmisartan IP 40mg, Chlorthalidone IP 12.5mg	1 Tablet	M/s Pharmafabrikon	5.89
14.	Doxorubicin Hydrochloride Liposome Injection 2mg/ml (20mg/vial) 10ml (Pegylated Liposomal) Concentrate for Infusion	Each ml contains: Doxorubicin Hydrochloride 2mg (Pegylated Liposomal) Water for Injection	10 ML vial	M/s Natco Pharma Limited / M/s Aureate Health Pvt. Ltd.	6459.20
15.	Cilnidipine + Telmisartan Tablet (Cilniblu T)	Each film coated tablet contains: Cilnidipine IP 10mg, Telmisartan IP 40mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd.	4.00
16.	Sofosbuvir + Velpatsvir Tablet	Each film coated tablet contains: Sofosbuvir 400mg, Velpatsvir 100mg	28's Tablets	M/s Natco Pharma Ltd. / M/s Aprazer Health Care Pvt. Ltd.	15481.86
17.	Sofosbuvir + Ledipasvir Tablet	Each film coated tablet contains: Sofosbuvir 400mg, Ledipasvir 90mg	1 Tablet	M/s Natco Pharma Ltd. / M/s Aprazer Health Care Pvt. Ltd.	589.92
18.	Etoricoxib + Paracetamol Tablet	Each film coated tablet contains: Etoricoxib 60mg, Paracetamol 325mg	1 Tablet	M/s Cadila Pharmaceuticals Limited	5.46
19.	Adapalene + Benzoyl Gel	Contains: Adapalene BP 0.1% w/w Benzoyl Peroxide IP eq. to Anhydrous Benzoyl Peroxide 2.5%w/w	1 GM	M/s Apex Laboratories Private Limited	18.42
20.	Teneligliptin + Metformin Tablet (Walaphage T 1000)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (SR)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Wallace Pharmaceuticals Pvt. Ltd.	10.09
21.	Teneligliptin + Metformin Tablet (Walaphage T 500)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 500mg (SR)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Wallace Pharmaceuticals Pvt. Ltd.	9.79

22.	Brimonidine + Timolol Eye Drops (New Albrim LST)	Contains: Brimonidine Tartrate IP 0.2%w/v, Timolol Maleate IP eq. to Timolol 0.5% w/v Sterile aqueous vehicle q.s.	1 ML	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alembic Pharmaceuticals Limited	18.75
23.	Glimiepiride + Metformin Tablet (GLYCOMET GP 3)	Each modified bi-layered ed tablet contains: Glimiepiride IP 3mg, Metformin Hydrochloride IP 500mg (ER)	1 Tablet	M/s Anphar Organics. / M/s USV Private Limited	6.89
24.	Paclitaxel (Protein bound Particles) for Injectable Suspension	Each vial contains: Paclitaxel IP 100mg/vial Lyophilized Human albumin q.s.	Each Pack	M/s Beta Drugs Ltd / M/s RPG Life Sciences Limited	11590.00
25.	Glimiepiride + Metformin Tablet (Glimison – M 0.5)	Each Uncoated bilayered Tablet contains: Glimiepiride IP 0.5mg & Metformin HCL IP 500mg (in prolonged release form)	1 Tablet	M/s Unison Pharmaceuticals Limited	1.79
26.	Teneligliptin + Metformin Tablet (Teneblu M Forte)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (SR)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd.	9.50
27.	Teneligliptin + Metformin Tablet (Teneblu M)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 500mg (SR)	1 Tablet	M/s Synokem Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd.	7.50
28.	Olmesartan + Amlodipine + Hydrochlorothiazide Tablet (Amlokind – 5)	Each film coated tablet contains: Olmesartan Medoxomil IP 40mg, Amlodipine Besilate IP eq. to Amlodipine 5mg & Hydrochlorothiazide IP 12.5	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited	12.95
29.	Travoprost + Timolol Maleate + Benzalkonium Eye Drops	Contains: Travoprost IP 0.004%w/v, Timolol Maleate IP eq. to Timolol 0.5% w/v, Benzalkonium Chloride Solution IP 0.01% v/v	1 ML	M/s Pure & Cure Healthcare Pvt. Ltd. / M/s LifeStar Pharma Private Limited	130.76
30.	Brimonidine + Timolol Maleate + Benzalkonium Eye Drops	Contains: Brimonidine Tartrate IP 0.2%w/v, Timolol Maleate IP eq. to Timolol 0.5% w/v, Benzalkonium Chloride Solution IP 0.02% v/v	1 ML	M/s Pure & Cure Healthcare Pvt. Ltd. / M/s LifeStar Pharma Private Limited	21.68
31.	Teneligliptin + Metformin Tablet (Glipijub M Forte)	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (ER)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Jubilant Lifesciences Limited	10.06
32.	Teneligliptin + Metformin Tablet (Glipijub M)	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 500mg (ER)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Jubilant Lifesciences Limited	9.79
33.	Teneligliptin + Metformin Tablet	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (ER)	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	6.25
34.	Teneligliptin + Metformin Tablet	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	5.358

		Metformin HCl 500mg (ER)			
35.	Travoprost + Timolol Eye Drops (Travisight -T)	Each ml contains: Travoprost IP 40mcg, Timolol Maleate IP eq. to Timolol 5mg	1 ML	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alembic Pharmaceuticals Ltd.	86.30
36.	Cilnidipine + Telmisartan + Chlorthalidone Tablet	Each filmcoated tablet contains: Cilnidipine 10mg, Telmisartan IP 40mg, Chlorthalidone 6.25mg	1 Tablet	M/s Safetab Life Science / M/s Lupin Limited	10.37
37.	Telmisartan + Hydrochlorothiazide Tablet (Telpha-H)	Each uncoated bilayered tablet contains: Telmisartan IP 40mg, Hydrochlorothiazide IP 12.5mg	1 Tablet	M/s Pharmafabrikon	7.14
38.	Ferrous Ascorbate + Folic Acid Tablet	Each film coated tablet contains: Ferrous Ascorbate eq. to Elemental Iron 100mg, Folic Acid IP 1.5mg,	1 Tablet	M/s Tirupati Medicare Ltd / M/s Zydus Cadila Healthcare Limited	8.89
39.	Doxorubicin Hydrochloride Injection	Each ml contains: Doxorubicin Hydrochloride IP 2mg (As pegylated liposomal) Water for Injection	25 ML vial	M/s Natco Pharma Ltd. / M/s Zydus Cadila Healthcare Limited	13473.68
40.	Rosuvastation + Clopidogrel Capsule	Each hard gelatine capsule contains: Rosuvastation IP 20mg (As pellets), Clopidogrel IP 75mg (as pellets)	1 Capsule	M/s Synokem Pharmaceuticals Limited / M/s INTAS Pharmaceuticals Limited	16.26
41.	Cilnidipine + Telmisartan Tablet (NEXOVAS T)	Each film coated tablet contains: Cilnidipine 10mg & Telmisartan IP 40mg	1 Tablets	M/s Macleods Pharmaceuticals Limited	7.67
42.	Cilnidipine + Telmisartan Tablet (ZITELMI -CL)	Each film coated tablet contains: Cilnidipine 10mg & Telmisartan IP 40mg	1 Tablets	M/s Akums Drugs & Pharmaceuticals Limited / M/s FDC Limited	7.14
43.	Diclofenac + Linseed Oil + Methyl Salicylate + Menthol + Benzyl Alcohol GEL (Dan)	contains: Diclofenac Diethylamine 1.16% w/w + Linseed Oil 3% w/w + Methyl Salicylate 10% w/w Menthol 5% w/w Benzyl Alcohol 1% w/w GEL base q. s.	1 GM	M/s Tuton Pharmaceuticals / M/s Unison Pharmaceuticals Pvt. Ltd.	1.40
44.	Telmisartan + Amlodipine Tablet (Telmiride - AM)	Each film coated tablets contains: Telmisartan IP 40mg + Amlodipine 5mg	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	2.99
45.	Cilnidipine + Telmisartan Tablet (Telmiride - LN)	Each film coated tablet contains: Cilnidipine 10mg & Telmisartan IP 40mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd.	3.57
46.	Voglibose + Metformin Tablet (Voglyson - M 0.2)	Each uncoated bilayered tablet Contains: Voglibose 0.2mg & Metformin Hydrochloride 500mg	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	3.20
47.	Voglibose + Glimepiride + Metformin Tablet (BETAGLIM 2 MV 0.3)	Each tablets contains: Voglibose IP 0.3mg, Glimepiride IP 2mg & Metformin (SR) 500mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Panacea Biotech Ltd.	9.37



48.	Voglibose + Glimepiride + Metformin Tablet (BETAGLIM 1 MV 0.3)	Each tablets contains: Voglibose IP 0.3mg, Glimepiride IP 1mg & Metformin (SR) 500mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Panacea Biotech Ltd.	8.03
49.	Voglibose + Glimepiride + Metformin Tablet (BETAGLIM 2 MV)	Each tablets contains: Voglibose IP 0.2mg, Glimepiride IP 2mg & Metformin (SR) 500mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Panacea Biotech Ltd.	8.48
50.	Voglibose + Glimepiride + Metformin Tablet (BETAGLIM 1 MV)	Each tablets contains: Voglibose IP 0.2mg, Glimepiride IP 1mg & Metformin (SR) 500mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Panacea Biotech Ltd.	7.14

Note:

- (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/190/58/2018/F

F. No. 8(58)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director